Construction of Macrophage Membrane-Coated Albumin Nanoparticles and Its Drug Delivery Evaluation For Glioma in Vitro
ZHANG Shu-yue1, HE Mei1, SUN Chen1, LI Juan-juan2, DING Bao-yue3, DING Xue-ying1*
1. Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China; 2. Department of Pharmacy, Changhai Hospital, Second Military Medical University, Shanghai 200082, China; 3. Medical College, Jiaxing University, Jiaxing 314001, China
Abstract：OBJECTIVE To construct membrane-coated biomimetic albumin nanoparticles loading with WEE1 kinase inhibitor adavosertib (MM-BSA/Ada), and evaluate its glioma drug-targeting feasibility in vitro. METHODS MM-BSA/Ada was prepared and the best mass ratio of membrane/BSA-np and adavosertib/BSA-np was screened. Particle size, Zeta potential, polydispersity index,morphology, and stability of MM-BSA/Ada were characterized. CCK-8 assay was conducted to detect the vector safety in bEnd.3 mouse brain endothelial cells and the anti-proliferation efficiency in C6 rat glioma cells. Its glioma targeting, blood-brain barrier (BBB) penetrating, and cellular uptake after BBB penetrating properties were investigated in vitro. RESULTS MM-BSA/Ada showed good stability, and the CCK-8 RESULTS showed that the membrane-coated albumin nanoparticles(MM-BSA) showed low toxicity to bEnd.3 mouse brain endothelial cells in vitro. The in vitro anti-proliferation activity (P<0.001), in vitro cellular uptake capability (P<0.001), in vitro BBB penetration efficiency (P<0.001) and the in vitro cellular uptake ability after BBB penetrating of MM-BSA/Ada (P<0.01) were significantly increased when comparing with the uncoated albumin nanoparticles (BSA-np)or free drugs.CONCLUSION MM-BSA/Ada shows good performance in glioma targeting drug delivery, which is expected to provide a new radio-sensitization strategy for glioma.
张姝月, 何美, 孙晨, 李鹃鹃, 丁宝月, 丁雪鹰. 巨噬细胞膜仿生白蛋白纳米体系的构建及其胶质瘤靶向递药性能评价[J]. 中国药学杂志, 2022, 57(8): 636-644.
ZHANG Shu-yue, HE Mei, SUN Chen, LI Juan-juan, DING Bao-yue, DING Xue-ying. Construction of Macrophage Membrane-Coated Albumin Nanoparticles and Its Drug Delivery Evaluation For Glioma in Vitro. Chinese Pharmaceutical Journal, 2022, 57(8): 636-644.
LAPOINTE S, PERRY A, BUTOWSKI N A. Primary brain tumours in adults [J]. Lancet, 2018, 392(10145): 432-446.
[2]
MA J, BENITEZ J A, LI J, et al. Inhibition of nuclear PTEN tyrosine phosphorylation enhances glioma radiation sensitivity through attenuated DNA repair [J]. Cancer Cell, 2019, 35(3): 504-518.
[3]
KAUR E, NAIR J, GHORAI A, et al. Inhibition of SETMAR-H3K36me2-NHEJ repair axis in residual disease cells prevents glioblastoma recurrence [J]. Neuro Oncol, 2020, 22(12): 1785-1796.
[4]
RORA A G L D, CERCHIONE C, MARTINELLI G, et al. A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target [J]. J Hematol Oncol, 2020, 13(1): 126. Doi: 10.1186/s13045-020-00959-2.
[5]
TAKEBE N, NAQASH A R, O′SULLIVAN C G, et al. Safety, antitumor activity, and biomarker analysis in a phase Ⅰ trial of the once-daily wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors [J]. Clin Cancer Res, 2021, 27(14): 3834-3844.
[6]
LHEUREUX S, CRISTEA M C, BRUCE J P, et al. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial [J]. Lancet, 2021, 397(10271): 281-292.
[7]
LIU J F, XIONG N, CAMPOS S M, et al. Phase Ⅱ Study of the WEE1 inhibitor adavosertib in recurrent uterine serous carcinoma [J]. J Clin Oncol, 2021, 39(14): 1531-1539.
[8]
CUNEO K C, MORGAN M A, SAHAI V, et al. Dose escalation trial of the wee1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer [J]. J Clin Oncol, 2019, 37(29): 2643-2650.
[9]
POKORNY J L, CALLIGARIS D, GUPTA S K, et al. The efficacy of the Wee1 inhibitor MK-1775 combined with temozolomide is limited by heterogeneous distribution across the blood-brain barrier in glioblastoma [J]. Clin Cancer Res, 2015, 21(8): 1916-1924.
[10]
MOREIRA D C, VENKATARAMAN S, SUBRAMANIAN A, et al. Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine [J]. J Neurooncol, 2020, 147(3): 531-545.
[11]
WU S, WANG S, GAO F, et al. Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma [J]. Neuro Oncol, 2018, 20(1): 78-91.
[12]
SANAI N, LI J, BOERNER J, et al. Phase 0 trial of AZD1775 in first-recurrence glioblastoma patients [J]. Clin Cancer Res, 2018, 24(16): 3820-3828.
[13]
SARCAR B, KAHALI S, PRABHU A H, et al. Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines [J]. Mol Cancer Ther, 2011, 10(12): 2405-2414.
[14]
LI J, WU J, BAO X, et al. Quantitative and mechanistic understanding of AZD1775 penetration across human blood-brain barrier in glioblastoma patients using an IVIVE-PBPK Modeling Approach [J]. Clin Cancer Res, 2017, 23(24): 7454-7466.
[15]
OBEROI R K, PARRISH K E, SIO T T, et al. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma [J]. Neuro Oncol, 2016, 18(1): 27-36.
[16]
LIN T, ZHAO P, JIANG Y, et al. Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy [J]. ACS Nano, 2016, 10(11): 9999-10012.
[17]
DENG G, PENG X, SUN Z, et al. Natural-killer-cell-inspired nanorobots with aggregation-induced emission characteristics for near-infrared-Ⅱ fluorescence-guided glioma theranostics [J]. ACS Nano, 2020, 14(9): 11452-11462.
[18]
LAI J, DENG G, SUN Z, et al. Scaffolds biomimicking macrophages for a glioblastoma NIR-Ib imaging guided photothermal therapeutic strategy by crossing Blood-Brain Barrier [J]. Biomaterials, 2019, 211: 48-56.
[19]
STEINHAUSER I M, LANGER K, STREBHARDT K M, et al. Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation [J]. Biomaterials, 2008, 29(29): 4022-4028.
[20]
HU C, LEI T, WANG Y, et al. Phagocyte-membrane-coated and laser-responsive nanoparticles control primary and metastatic cancer by inducing anti-tumor immunity [J]. Biomaterials, 2020, 255: 120159. Doi:10.1016/j.biomaterals.2020.120159.
[21]
CHEN Q, LIU Z. Albumin carriers for cancer theranostics: a conventional platform with new promise [J]. Adv Mater, 2016, 28(47): 10557-10566.
[22]
HOOGENBOEZEM E N, DUVALL C L. Harnessing albumin as a carrier for cancer therapies [J]. Adv Drug Deliv Rev, 2018, 130: 73-89.
[23]
ARVANITIS C D, FERRARO G B, JAIN R K. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases [J]. Nat Rev Cancer, 2020, 20(1): 26-41.
[24]
GRIFFITH J I, RATHI S, ZHANG W, et al. Addressing BBB heterogeneity: a new paradigm for drug delivery to brain Tumors [J]. Pharmaceutics, 2020, 12(12):1205. Doi: 10.3390/pharmacetics12121205.
[25]
GUO J, HUANG L. Membrane-core nanoparticles for cancer nanomedicine [J]. Adv Drug Deliv Rev, 2020, 156: 23-39.
[26]
MENDANHA D, VIEIRA D C J, FERREIRA H, et al. Biomimetic and cell-based nanocarriers -New strategies for brain tumor targeting [J]. J Controll Release, 2021, 337: 482-493.
2022, Vol. 57 
